GNI : Q2 FY2022 Financial Results Corporate Presentation

GNI Group Ltd.	FY2022 Q2 Year to Date Financial Results
	Corporate Presentation
	Aug 17th, 2022
	We Bring New Hope to Patients

© 2022 GNI Group Ltd. All rights reserved	Securities Code:	2160
	1

We Bring New Hope to Patients

Forward-looking Statements

This presentation contains statements concerning the current plans, expectations and strategies of GNI Group Ltd. (GNI Group). Any statements contained herein that pertain to future operating performance and that are not historic facts are forward- looking statements. Forward-looking statements may include, but are not limited to, words such as "believe," "plan," "strategy," "expect," "forecast," "possibility" and similar words that describe future operating activities, business performance, events or conditions. Forward-looking statements, whether spoken or written, are based on judgments made by the management of GNI Group, based on information that is currently available to it. As such, these forward-looking statements are subject to various risks and uncertainties, and actual business results may vary substantially from the forecasts expressed or implied in forward- looking statements. Consequently, investors are cautioned not to place undue reliance on forward-looking statements.

The information contained in this presentation does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. Any decision to invest in or acquire securities of GNI Group must be based wholly on the information contained in the preliminary offering circular issued or to be issued by GNI Group in connection with any such offer and not on the contents hereof.

This English summary translation is for convenience only. To the extent there is any discrepancy between this English translation and the original Japanese version, please refer to the Japanese version.

Note: In places, pro forma figures in the pages which follow may be rounded to underscore direction of the business.

© 2022 GNI Group Ltd. All rights reserved

2

We Bring New Hope to Patients

Agenda

Business Overview

Ying Luo (罗楹), PhD

President and Chief Executive Officer

Financial Overview

Joseph Francis Meyer

Chief Financial Officer

Questions and Answers

Ying Luo

Joseph Francis Meyer

Akihiro Nakano (IR)

© 2022 GNI Group Ltd. All rights reserved

3

We Bring New Hope to Patients

2022Q2YTD: Maintaining Growth and Strategic Initiatives

• Posted consolidated revenue JPY 8.1 bn yen in the 1st half of 2022, up 26.1% YoY.
• R&D progress continues at both BC and Cullgen
• BAB growth solid
• BC IPO application to HKEX
• Strategic opportunities for expansion in Japan under review

Growth

Continues

• JPY 8.1 bn in revenue, up 26.1% YoY
• On track for full-year budget

R&D Progress	Business	Strategic
• Expanding	Expansion	Financing
Pirfenidone	• Bringing Biomaterial	• BC IPO application
indications at BC	business to East Asia	to HKEX
• Protein degrader	• Aligning corporate
IND in China for
structure accordingly
Cullgen

BC: Beijing Continent Pharmaceutical Co, Ltd.	BAB: Berkeley Advanced Biomaterials LLC
© 2022 GNI Group Ltd. All rights reserved
	4

We Bring New Hope to Patients

Key Business Growth Initiatives - Progress

ETUARY®	Driving the Group's financial stability

•Continues to post the record sales in local currency terms

Drug Discovery	Investing in future growth

•Cullgen's TPD* oncology drug obtained IND approval in China; commencing Ph1 clinical trial in China

•Steady progress in BC's new drug pipeline: ETUARY® for Pneumoconiosis in Ph3 clinical trial; F351 Ph2 clinical trial in progress; F351 Ph2 results published in renowned academic journal in the US, Clinical Gastroenterology and Hepatology

•GNI USA F351 Ph2 clinical trial for NASH being discussed with FDA

Biomaterial	Expanding internationally
•Deliberating corporate re-organization to help catapult the business internationally
Strategic Investments	Leveraging industry expertise to diversify sources of revenue and growth

• $15 million committed, $4.5 million invested so far as an LP to a biotech specialist fund in China as an additional means to insource innovation

*TPD: Targeted Protein Degradation

© 2022 GNI Group Ltd. All rights reserved

5